|
1
|
Baynes RD, Dansey RD, Klein JL, Hamm C,
Campbell M, Abella E and Peters WP: High-dose chemotherapy and
hematopoietic stem cell transplantation for breast cancer: Past or
future? Semin Oncol. 28:377–388. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Collaborative Group on Hormonal Factors in
Breast Cancer. Familial breast cancer: Collaborative reanalysis of
individual data from 52 epidemiological studies including 58,209
women with breast cancer and 101,986 women without the disease.
Lancet. 358:1389–1399. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ripperger T, Gadzicki D, Meindl A and
Schlegelberger B: Breast cancer susceptibility: Current knowledge
and implications for genetic counselling. Eur J Hum Genet.
17:722–731. 2009. View Article : Google Scholar
|
|
5
|
Elstrodt F, Hollestelle A, Nagel JH, Gorin
M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP and
Schutte M: BRCA1 mutation analysis of 41 human breast cancer cell
lines reveals three new deleterious mutants. Cancer Res. 66:41–45.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Birgisdottir V, Stefansson OA,
Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG and Eyfjord JE:
Epigenetic silencing and deletion of the BRCA1 gene in sporadic
breast cancer. Breast Cancer Res. 8:R382006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wilson CA, Ramos L, Villaseñor MR, Anders
KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D,
et al: Localization of human BRCA1 and its loss in high-grade,
non-inherited breast carcinomas. Nat Genet. 21:236–240. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lakhani SR, Van De Vijver MJ, Jacquemier
J, Anderson TJ, Osin PP, McGuffog L and Easton DF: The pathology of
familial breast cancer: Predictive value of immunohistochemical
markers estrogen receptor, progesterone receptor, HER-2, and p53 in
patients with mutations in BRCA1 and BRCA2. J Clin Oncol.
20:2310–2318. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Palacios J, Honrado E, Osorio A, Cazorla
A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C,
et al: Phenotypic characterization of BRCA1 and BRCA2 tumors based
in a tissue microarray study with 37 immunohistochemical markers.
Breast Cancer Res Treat. 90:5–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moynahan ME, Chiu JW, Koller BH and Jasin
M: Brca1 controls homology-directed DNA repair. Mol Cell.
4:511–518. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tutt A, Bertwistle D, Valentine J, Gabriel
A, Swift S, Ross G, Griffin C, Thacker J and Ashworth A: Mutation
in Brca2 stimulates error-prone homology-directed repair of DNA
double-strand breaks occurring between repeated sequences. EMBO J.
20:4704–4716. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tutt A and Ashworth A: The relationship
between the roles of BRCA genes in DNA repair and cancer
predisposition. Trends Mol Med. 8:571–576. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huen MS and Chen J: Assembly of checkpoint
and repair machineries at DNA damage sites. Trends Biochem Sci.
35:101–108. 2010. View Article : Google Scholar
|
|
14
|
Ashworth A: A synthetic lethal therapeutic
approach: Poly(ADP) ribose polymerase inhibitors for the treatment
of cancers deficient in DNA double-strand break repair. J Clin
Oncol. 26:3785–3790. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Herceg Z and Wang ZQ: Functions of
poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity
and cell death. Mutat Res. 477:97–110. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wiltshire TD, Lovejoy CA, Wang T, Xia F,
O’Connor MJ and Cortez D: Sensitivity to poly(ADP-ribose)
polymerase (PARP) inhibition identifies ubiquitin-specific
peptidase 11 (USP11) as a regulator of DNA double-strand break
repair. J Biol Chem. 285:14565–14571. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bryant HE, Schultz N, Thomas HD, Parker
KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Farmer H, McCabe N, Lord CJ, Tutt AN,
Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I,
Knights C, et al: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature. 434:917–921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fong PC, Boss DS, Yap TA, Tutt A, Wu P,
Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, et
al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA
mutation carriers. N Engl J Med. 361:123–134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tutt A, Robson M, Garber JE, Domchek SM,
Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler
RK, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in
patients with BRCA1 or BRCA2 mutations and advanced breast cancer:
A proof-of-concept trial. Lancet. 376:235–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Murai J, Huang SY, Das BB, Renaud A, Zhang
Y, Doroshow JH, Ji J, Takeda S and Pommier Y: Differential trapping
of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res.
72:5588–5599. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang Z and Klionsky DJ: Mammalian
autophagy: Core molecular machinery and signaling regulation. Curr
Opin Cell Biol. 22:124–131. 2010. View Article : Google Scholar :
|
|
23
|
Dalby KN, Tekedereli I, Lopez-Berestein G
and Ozpolat B: Targeting the prodeath and prosurvival functions of
autophagy as novel therapeutic strategies in cancer. Autophagy.
6:322–329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Akar U, Ozpolat B, Mehta K, Fok J, Kondo Y
and Lopez-Berestein G: Tissue transglutaminase inhibits autophagy
in pancreatic cancer cells. Mol Cancer Res. 5:241–249. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Levine B and Kroemer G: Autophagy in the
pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rottenberg S, Jaspers JE, Kersbergen A,
van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M,
Zevenhoven J, Lau A, et al: High sensitivity of BRCA1-deficient
mammary tumors to the PARP inhibitor AZD2281 alone and in
combination with platinum drugs. Proc Natl Acad Sci USA.
105:17079–17084. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Carey L, Winer E, Viale G, Cameron D and
Gianni L: Triple-negative breast cancer: Disease entity or title of
convenience? Nat Rev Clin Oncol. 7:683–692. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ashrafi G and Schwarz TL: The pathways of
mitophagy for quality control and clearance of mitochondria. Cell
Death Differ. 20:31–42. 2013. View Article : Google Scholar
|
|
29
|
Akar U, Chaves-Reyez A, Barria M, Tari A,
Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G and Ozpolat
B: Silencing of Bcl-2 expression by small interfering RNA induces
autophagic cell death in MCF-7 breast cancer cells. Autophagy.
4:669–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tekedereli I, Alpay SN, Akar U, Yuca E,
Ayugo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G and Ozpolat
B: Therapeutic silencing of Bcl-2 by systemically
administered-siRNA nanotherapeutics inhibits tumor growth by
autophagy and apoptosis and enhances the efficacy of chemotherapy
in orthotopic xenograft models of ER (−) and ER (+) breast cancer.
Mol Ther Nucleic Acids. 2:e1212013. View Article : Google Scholar
|
